Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome.

University of Colorado, Pediatrics, Aurora, Colorado, United States, , University of Colorado, Cardiovascular Pulmonary Research, Aurora, Colorado, United States
Antioxidants & Redox Signaling (Impact Factor: 7.67). 12/2012; DOI: 10.1089/ars.2012.4799
Source: PubMed

ABSTRACT Aims: Pulmonary hypertension (PH) is characterized by an oxidant/antioxidant imbalance that promotes abnormal vascular responses. Reactive oxygen species (ROS) such as superoxide (O2•-) contribute to the pathogenesis of pulmonary hypertension (PH), and vascular responses including remodeling and inflammation. This study sought to investigate the protective role of a pharmacological catalytic antioxidant, a superoxide dismutase (SOD) mimetic (MnTE-2-PyP), in hypoxia-induced PH, vascular remodeling and NALP3 (NACHT, LRR and PYD domains-containing protein 3) mediated inflammation. Results: Mice (C57/BL6) were exposed to hypobaric hypoxic conditions while sub-cutaneous injections of MnTE-2-PyP (5mg/kg) or PBS were given 3x weekly for up to 35 days. MnTE-2-PyP treated groups demonstrated protection against increased right ventricular systolic pressure (RVSP) and RV hypertrophy. Vascular remodeling, assessed by vascular cell proliferation (Ki67), small vessel muscularization (α-smooth muscle actin), and extracellular matrix modulation (hyaluronan), was attenuated by MnTE-2-PyP treatment. Hypoxia-induced activation of the NALP3 inflammasome pathway, measured by NALP3 expression, caspase-1 activation, and IL-1β and IL-18 production, was also attenuated by MnTE-2-PyP. Innovation: This study is the first to demonstrate activation of the NALP3 inflammasome with cleavage of caspase-1 and release of active IL-1 β and IL-18 in chronic hypoxic pulmonary hypertension, as well as its attenuation by the SOD mimetic, MnTE-2-PyP. Conclusion: The ability of the SOD mimetic to scavenge extracellular O2•- supports our previous observations in EC-SOD overexpressing mice that implicate extracellular oxidant/anti-oxidant imbalance in hypoxic pulmonary hypertension and its role in hypoxia induced inflammation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The enzyme extracellular superoxide dismutase (EC-SOD; SOD3) is a major antioxidant defense in lung and vasculature. A nonsynonomous single-nucleotide polymorphism in EC-SOD (rs1799895) leads to an arginine to glycine amino acid substitution at position 213 (R213G) in the heparin-binding domain. In recent human genetic association studies, this single-nucleotide polymorphism attenuates the risk of lung disease, yet paradoxically increases the risk of cardiovascular disease. Methods and Results Capitalizing on the complete sequence homology between human and mouse in the heparin-binding domain, we created an analogous R213G single-nucleotide polymorphism knockin mouse. The R213G single-nucleotide polymorphism did not change enzyme activity, but shifted the distribution of EC-SOD from lung and vascular tissue to extracellular fluid (eg, bronchoalveolar lavage fluid and plasma). This shift reduces susceptibility to lung disease (lipopolysaccharide-induced lung injury) and increases susceptibility to cardiopulmonary disease (chronic hypoxic pulmonary hypertension). Conclusions We conclude that EC-SOD provides optimal protection when localized to the compartment subjected to extracellular oxidative stress: thus, the redistribution of EC-SOD from the lung and pulmonary circulation to the extracellular fluids is beneficial in alveolar lung disease but detrimental in pulmonary vascular disease. These findings account for the discrepant risk associated with R213G in humans with lung diseases compared with cardiovascular diseases.
    Circulation Cardiovascular Genetics 08/2014; 7(5). DOI:10.1161/CIRCGENETICS.113.000504 · 5.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pulmonary artery hypertension (PAH) is characterized by vascular remodeling, high pulmonary blood pressure, and right ventricular hypertrophy. Oxidative stress, inflammation and pulmonary artery remodeling are important components in PAH. Ellagic acid (EA) is a phenolic compound with anti-oxidative, anti-inflammatory, and anti-proliferative properties. This study aimed to investigate whether EA could prevent the development of monocrotaline (MCT)-induced PAH in rats.Methods Male Sprague-Dawley rats received EA (30 and 50 mg/kg/day) or vehicle one day after a single-dose of monocrotaline (MCT, 60 mg/kg). Hemodynamic changes, right ventricular hypertrophy, and lung morphological features were assessed 4 weeks later. Activation of the NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome pathway in the lungs was assessed using western blot analysis.ResultsMCT induced PAH, oxidative stress, and NLRP3 inflammasome activation in vehicle-treated rats. EA reduced right ventricle systolic pressure, the right ventricular hypertrophy and the wall thickness/external diameter ratio of the pulmonary arteries compared with vehicle. EA also inhibited the MCT-induced elevation of oxidative stress, NLRP3, caspase-1, IL-β in the lungs and the elevated levels of brain natriuretic peptide (BNP) and inflammatory cytokines in serum.Conclusions Ellagic acid ameliorates monocrotaline-induced pulmonary artery hypertension via exerting its anti-oxidative property inhibiting NLRP3 inflammasome signal pathway in rats.
    International Journal of Cardiology 11/2014; 180. DOI:10.1016/j.ijcard.2014.11.161 · 6.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Research studying the role of inflammation in hypertension and cardiovascular disease has flourished in recent years; however, the exact mechanisms by which the activated immune cells lead to the development and maintenance of hypertension remain to be elucidated. The objectives of this brief review are to summarize and discuss the most recent findings in the field, with special emphasis on potential therapeutics to treat or prevent hypertension. This review will cover novel immune cell subtypes recently associated to the disease including the novel role of cytokines, toll-like receptors, and inflammasomes in hypertension.
    Current Hypertension Reports 01/2015; 17(1):507. DOI:10.1007/s11906-014-0507-z · 3.90 Impact Factor